Method for elimination of rheumatoid factor interference in diagnostic assays
US5698393A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 18, 1995 |
| Grant date | Dec 16, 1997 |
| Priority date | — |
| Expiry date | Aug 18, 2015 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/967
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A method for treating biological samples, e.g., human sera or plasma, suspected of containing rheumatoid factors to eliminate cross-reactivity and false positive assay results in IgM immunoassays that are caused by the presence of rheumatoid factors in these biological samples. In one aspect, the method comprises diluting a biological sample with a sufficient amount of rheumatoid factor neutralization buffer to cause the pH of resulting reaction mixtures containing this sample and a solid phase material to be sufficiently low to cause rheumatoid factors in those mixtures to reduce their affinity to IgG antibodies to such an extent that they will not form a complex with IgG antibodies bound to the solid phase material, thereby facilitating the removal of these rheumatoid factors from the mixtures prior to the detection phase of a diagnostic assay. In another aspect of the invention, the method comprises introducing to a solid phase material containing a binding member-antibody complex a sufficient amount of rheumatoid factor neutralization buffer having a pH sufficiently low to cause rheumatoid factors bound to IgG antibodies bound to the solid phase material to reduce their affinit…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.